Emerging ibrutinib-based combinations in CLL

(1:56)

Update on BTK inhibitors for CLL: Ibrutinib pus the new kids on the block: Are they better?

(21:42)

CLL: Chemotherapy and Ibrutinib based regimens

(25:38)

The role of ibrutinib in the frontline treatment of young patients with CLL

(2:6)

CLL: Long-term updates on ibrutinib and idelalisib

(25:9)

Mechanisms of Ibrutinib Resistance in Chronic Lymphocytic Leukemia

(10:21)

Adverse Events of Ibrutinib in Chronic Lymphocytic Leukemia

(11:28)

Ibrutinib treatment and its associated risk factors

(1:56)

Results from the GLOW Clinical Trial in Chronic Lymphocytic Leukemia

(4:56)

Dr. Tendler on the Mechanism of Action of Ibrutinib

(2:5)

Dr. James on Update of Ibrutinib for Chronic Lymphocytic Leukemia

(1:29)

Acalabrutinib in ibrutinib-intolerant CLL patients: opening new doors

(4:)

Acalabrutinib May Be an Alternative to Ibrutinib For Treatment of CLL

(1:37)

Ibrutinib resistance-mechanisms and options in CLL

(29:14)

Achieving undetectable MRD with ibrutinib plus venetoclax for CLL

(1:53)

Treatment Strategies With Ibrutinib in CLL

(3:22)

ASH Impact Series: Kristie Blum, MD - Examining the New Indications for Ibrutinib

(6:27)

Long-term outcomes and toxicities of ibrutinib in CLL

(1:22)

Potential Ibrutinib Toxicities

(5:11)

Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax

(2:43)